Form 10-Q · Quarterly report
Veeva Systems 10-Q, filed Aug 27, 2026
- Filed
- CIK
- 0001393052
- Accession no.
- 0001393052-26-000036
Summary
Veeva Systems reported total revenues of $3,195 million and net income of $909 million for its fiscal year ended January 31, 2026, with total revenues up 16% year over year and subscription revenues of $2,684 million up 17%. The company said revenues from its R&D and Quality Solutions are expected to increase as a percentage of both subscription and total revenues in the future.
Key points
- For the six months ended July 31, 2026, subscription revenues were 83% of total revenues and professional services and other revenues 17%.
- Commercial Solutions accounted for 46% of subscription revenues and R&D and Quality Solutions 54% in the six months ended July 31, 2026.
- As of January 31, 2026, Veeva served 1,552 customers, including 767 Commercial Solutions customers and 1,196 R&D and Quality Solutions customers.
- Veeva's subscription offerings are grouped into Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud, with computing infrastructure provided by third parties including Amazon Web Services and Salesforce, Inc.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION Overview Veeva is the leading provider of industry cloud solutions for the global life sciences industry. Our offerings span applications, agents, data, and consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from R&D through commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.